1 / 17

2011 NYU NMVB Report

2011 NYU NMVB Report. NYU Dept of Cardiothoracic Surgery NYU Dept of Pathology Monday November 7 th , 2011. Personnel @ NYU. Dept. Cardiothoracic Surgery. Harvey Pass, MD (Surgeon, NYU Steering Committee Member & PI). Audrey Sorensen, RN (Research Nurse Coordinator). Ryan Harrington

reilly
Télécharger la présentation

2011 NYU NMVB Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2011 NYU NMVB Report NYU Dept of Cardiothoracic Surgery NYU Dept of Pathology Monday November 7th, 2011

  2. Personnel @ NYU Dept. Cardiothoracic Surgery Harvey Pass, MD (Surgeon, NYU Steering Committee Member & PI) Audrey Sorensen, RN (Research Nurse Coordinator) Ryan Harrington (Lab Technician, Thoracic Lab) Angela Pittman (Research Project Coordinator) Dept. Pathology Jonathan Melamed, MD (Pathologist, NYU Steering Committee Member) Ruth Pe Benito (Bioresource Manager) Monica Gorman (Research Coordinator) Rachel Ruoff (Lab Technician, Pathology Lab)

  3. NYU MVB IRB Amendment Approval Amendment to IRB (approved on 10/27 /11) Amendment includes the following statement in the consent: “The NYU School of Medicine is collaborating with the University of Pittsburgh to create and maintain the Mesothelioma Virtual Bank (MVB). Clinical information and biologic samples that are free of any personal health identifiers are shared in accordance with HIPAA standards. This data is used to advance the scientific understanding of Mesothelioma. “

  4. NYU Additions to MVB 2011

  5. NYU MVB Biospecimen Accrual

  6. NYU MVB tissue accrual • Emphasis on accruing extrapleural pneumonectomy cases

  7. NYU MVB Paraffin TMA 1 • NYU MVB Paraffin TMA 1 • 2 identical TMA Blocks • 37 cases - arrayed over 2 blocks • 37 Tumor + 4 Control • 8 Cell lines • Supplementary TMA • 9 Cases (additional cores for TMA1) • 9 Tumor +1 Control • Block A • Block B

  8. Map for Paraffin TMA

  9. QA Steps for TMA (slide A) • Evaluation for presence of tissue and sampling accuracy based on tumor (9 of 37 cases missing across the two TMAs – added in supplementary block) • IHC stain to evaluate antigenicity of tissue: WT-1, Calretinin

  10. QA Table for TMA

  11. Map for Supplementary Paraffin TMA

  12. Frozen TMA

  13. High Density Frozen TMA: Construction 2009-2010 2010-2011 Oil Frozen Array mold

  14. Ischemia-Fixation TMA Pre-analytic variables in FFPE Varied duration from devascularization to preservation: ISCHEMIA time (minutes to hours) Varied duration of fixation: 0- 36 hours Varied tissue processor protocols across institutions Design: Timed experiment with varied ischemia/fixation times of tissue –constituted into TMA (n = 3+) Outcome: TMA slides for 1) investigators to measure preservation of marker of interest against different pre-analytic variables 2) NMVB biospecimen science – to determine biomarkers that reflect early ischemic effects for rating of core preservation on NMVB TMAs.

  15. Ischemia-Fixation Meso TMA

  16. Diagnostic marker durability: Necrosis, ischemia, overfixation (WT-1, Calretinin)(autopsy vs biopsy material)Impact of preanalytic variables: Tissue expression of current serum /pleural fluid biomarkers:Tools: Frozen TMA & Ischemia/Fixation TMA Biospecimen Science

More Related